Related Experiment Videos
[Dantrolene. Pharmacological and therapeutic aspects]
M U Gerbershagen1, M Fiege, T Krause
1Klinik und Poliklinik für Anästhesiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg. gerbershagen@uke.uni-hamburg.de
Der Anaesthesist
|April 1, 2003
Summary
Malignant hyperthermia (MH) is a serious genetic disorder triggered by anesthesia. Dantrolene is the sole effective treatment, targeting the ryanodine receptor to improve patient outcomes.
Area of Science:
- Pharmacology
- Molecular Biology
- Genetics
Context:
- Malignant hyperthermia (MH) is a critical genetic disorder affecting skeletal muscle during anesthesia.
- Anesthetic agents like volatile anesthetics and depolarizing muscle relaxants are known triggers for MH.
- Dantrolene is the primary therapeutic agent for MH, significantly reducing mortality.
Purpose:
- To elucidate the specific molecular target of dantrolene in treating malignant hyperthermia.
- To understand the mechanism by which dantrolene inhibits skeletal muscle excitation-contraction coupling.
- To review the current therapeutic applications and limitations of dantrolene.
Summary:
- Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle.
- Dantrolene, a skeletal muscle relaxant, is the only specific treatment for MH.
- Recent research identifies the ryanodine receptor as the direct molecular target of dantrolene, explaining its mechanism in MH and other conditions like neuroleptic malignant syndrome and spasticity.
Impact:
- Identifies the ryanodine receptor as the direct molecular target of dantrolene.
- Provides a mechanistic understanding of dantrolene's efficacy in malignant hyperthermia and related disorders.
- Highlights challenges in dantrolene preparation and the need for improved therapeutic agents.